Isabelle Treilleux

28.2k total citations · 1 hit paper
219 papers, 7.9k citations indexed

About

Isabelle Treilleux is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Isabelle Treilleux has authored 219 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 78 papers in Molecular Biology and 36 papers in Cancer Research. Recurrent topics in Isabelle Treilleux's work include Ovarian cancer diagnosis and treatment (32 papers), Cancer-related Molecular Pathways (20 papers) and Breast Cancer Treatment Studies (19 papers). Isabelle Treilleux is often cited by papers focused on Ovarian cancer diagnosis and treatment (32 papers), Cancer-related Molecular Pathways (20 papers) and Breast Cancer Treatment Studies (19 papers). Isabelle Treilleux collaborates with scholars based in France, United States and Belgium. Isabelle Treilleux's co-authors include Jean‐Yves Blay, Nathalie Bendriss‐Vermare, Christophe Caux, Thomas Bachelot, Sophie Goddard‐Léon, Christine Ménétrier‐Caux, Alain Puisieux, Michael Gobert, Isabelle Durand and Isabelle Ray‐Coquard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Isabelle Treilleux

204 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

2009 562 citations Michael Gobert, Isabelle Treilleux et al. Cancer Research profile →

Peers

Countries citing papers authored by Isabelle Treilleux

Since Specialization

Citations

This map shows the geographic impact of Isabelle Treilleux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Treilleux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Treilleux more than expected).

Fields of papers citing papers by Isabelle Treilleux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Treilleux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Treilleux. The network helps show where Isabelle Treilleux may publish in the future.

Co-authorship network of co-authors of Isabelle Treilleux

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Treilleux. A scholar is included among the top collaborators of Isabelle Treilleux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Treilleux. Isabelle Treilleux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes 2025 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), Isabelle Treilleux, Valentin Wucher, Macarena Villagrán‐García, (unknown), Daniel Pissaloux, Sandrine Paindavoine, Valéry Attignon, Géraldine Picard, Véronique Rogemond, (unknown), Laurie Tonon, (unknown), Alain Viari, Bertrand Dubois, Jérôme Honnorat, (unknown)	0
2	34O ROCSAN: A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy – Preliminary results 2024 ·ESMO Open ·(unknown), Audrey Bellesœur, (unknown), (unknown), Frédéric Bigot, (unknown), Antoine Angelergues, (unknown), Elsa Kalbacher, Coriolan Lebreton, (unknown), Claudia Lefeuvre‐Plesse, (unknown), (unknown), (unknown), Sarah Bétrian, M-A Mouret-Reynier, Isabelle Treilleux, (unknown), Alexandra Léary	0
3	The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers 2024 ·Science Translational Medicine ·(unknown), Carlos Gomez‐Roca, Sylvie Chabaud, Céline Rodriguez, (unknown), (unknown), (unknown), (unknown), Isabelle Treilleux, Lauriane Eberst, C. Terret, (unknown), (unknown), David Pérol, Jean‐Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier‐Caux, Nathalie Bendriss‐Vermare, Philippe A. Cassier	32
4	Gynecological carcinosarcomas: Overview and future perspectives 2023 ·Bulletin du Cancer ·L. Collet, (unknown), (unknown), Pierre Méeus, Nicolás Chopin, (unknown), (unknown), (unknown), (unknown), Adrien Buisson, Isabelle Treilleux, Isabelle Ray‐Coquard	0
5	Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα ⁺ breast cancer 2023 ·EMBO Molecular Medicine ·Coralie Poulard, (unknown), (unknown), Julien Jacquemetton, (unknown), Loay Kassem, Benoîte Méry, Christine Lasset, (unknown), Isabelle Treilleux, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer	9
6	Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca2+ traffic and response to neoadjuvant chemotherapy 2023 ·Cell Death and Disease ·Minh Quang Dương, Rudy Gadet, Isabelle Treilleux, (unknown), (unknown), Olivier Marcillat, Philippe Gonzalo, Ivan Mikaélian, Nikolay Popgeorgiev, Ruth Rimokh, Germain Gillet	5
7	A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 2022 ·Journal of Personalized Medicine ·Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, (unknown), Ellen Blanc, (unknown), Isabelle Treilleux, (unknown), (unknown), Pierre Guibert, Matthieu Sarabi, (unknown), (unknown), Clélia Coutzac, Isabelle Ray‐Coquard, Patrice Peyrat, Pierre Méeus, Michel Rivoire, Aurélien Dupré, Anà Hennino	2
8	CD163⁺ tumor‐associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes 2020 ·Clinical & Translational Immunology ·Rodrigo Nalio Ramos, (unknown), Margaux Hubert, Maude Ardin, Isabelle Treilleux, Carola H. Ries, Emilie Lavergne, Sylvie Chabaud, (unknown), Olivier Trédan, (unknown), Fábio Martins Laginha, Wilfrid Richer, Eliane Piaggio, José Alexandre Marzagão Barbuto, Christophe Caux, Christine Ménétrier‐Caux, Nathalie Bendriss‐Vermare	54
9	Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History 2020 ·Cancers ·Mehdi Brahmi, (unknown), Isabelle Treilleux, Daniel Pissaloux, Isabelle Ray‐Coquard, Armelle Dufresne, Hélène Vanacker, (unknown), Pierre Méeus, Marie‐Pierre Sunyach, Amine Bouhamama, Marie Karanian, Alexandra Meurgey, Jean‐Yves Blay, Franck Tirode	25
10	Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10 2018 ·Cancer Research ·(unknown), Nikolay Popgeorgiev, Loay Kassem, Soleilmane Omarjee, (unknown), Ivan Mikaélian, Jonathan Lopez, Rudy Gadet, Olivier Marcillat, Isabelle Treilleux, Bruno O. Villoutreix, Ruth Rimokh, Germain Gillet	34
11	Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment 2013 ·Cancer Research ·Isabelle Le Mercier, Dominique Poujol, Amélien Sanlaville, Vanja Sisirak, Michael Gobert, Isabelle Durand, Bertrand Dubois, Isabelle Treilleux, Jacqueline Marvel, Jaromir Vlach, Jean‐Yves Blay, Nathalie Bendriss‐Vermare, Christophe Caux, Isabelle Puisieux, Nadège Goutagny	156
12	ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells 2012 ·Cancer Research ·Julien Faget, Nathalie Bendriss‐Vermare, Michael Gobert, Isabelle Durand, Daniel Olive, Cathy Biota, Thomas Bachelot, Isabelle Treilleux, Sophie Goddard‐Léon, Emilie Lavergne, Sylvie Chabaud, Jean‐Yves Blay, Christophe Caux, Christine Ménétrier‐Caux	159
13	Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression 2012 ·Cancer Research ·Vanja Sisirak, Julien Faget, Michael Gobert, Nadège Goutagny, Nelly Vey, Isabelle Treilleux, Sarah Renaudineau, Gaelle Poyet, Sana Intidhar Labidi‐Galy, Sophie Goddard‐Léon, Isabelle Durand, Isabelle Le Mercier, Agathe Bajard, Thomas Bachelot, Alain Puisieux, Isabelle Puisieux, Jean‐Yves Blay, Christine Ménétrier‐Caux, Christophe Caux, Nathalie Bendriss‐Vermare	269
14	ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion 2012 ·Cancer Research ·Julie A. Vendrell, Aurélie Thollet, Nhan Trung Nguyen, Sandra E. Ghayad, Stéphanie Vinot, Ivan Bièche, (unknown), Véronique Josserand, Jean‐Luc Coll, Pierre Roux, Laura Corbo, Isabelle Treilleux, Ruth Rimokh, Pascale A. Cohen	95
15	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer 2011 ·Cancer Research ·Sana Intidhar Labidi‐Galy, Vanja Sisirak, Pierre Méeus, Michael Gobert, Isabelle Treilleux, Agathe Bajard, Jean‐Damien Combes, Julien Faget, François Mithieux, (unknown), Olivier Trédan, Isabelle Durand, Christine Ménétrier‐Caux, Christophe Caux, Jean‐Yves Blay, Isabelle Ray‐Coquard, Nathalie Bendriss‐Vermare	187
16	Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells 2011 ·Cancer Research ·Julien Faget, Cathy Biota, Thomas Bachelot, Michael Gobert, Isabelle Treilleux, Nadège Goutagny, Isabelle Durand, (unknown), Jean‐Yves Blay, Christophe Caux, Christine Ménétrier‐Caux	103
17	BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy 2010 ·Clinical Cancer Research ·Charles Dumontet, Maryla Krajewska, Isabelle Treilleux, John R. Mackey, Miguel Martín, (unknown), Laurence Lafanéchère, John C. Reed	33
18	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome breakdown → 2009 ·Cancer Research ·Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare, Thomas Bachelot, Sophie Goddard‐Léon, Vanessa Arfi, Cathy Biota, (unknown), Isabelle Durand, Daniel Olive, Solène Perez, Nicolas Pasqual, Christelle Fauré, Isabelle Ray‐Coquard, Alain Puisieux, Christophe Caux, Jean‐Yves Blay, Christine Ménétrier‐Caux	562
19	Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel 2008 ·Clinical Cancer Research ·Carlos M. Galmarini, Isabelle Treilleux, Fátima Cardoso, Chantal Bernard-Marty, Virginie Durbecq, David Gancberg, Marie-Christine Bissery, Marianne Paesmans, Denis Larsimont, Martine Piccart, Angelo Di Leo, Charles Dumontet	55
20	Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases 2007 ·Cancer Research ·Yingshe Zhao, Richard Bachelier, Isabelle Treilleux, Philippe Pujuguet, Olivier Peyruchaud, Roland Baron, (unknown), Philippe Clézardin	174

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact